Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | AGO-OVAR 2.29/ENGOT-ov34: atezolizumab vs placebo + bevacizumab w/ chemo recurrent ovarian cancer

Frederik Marmé, MD, PhD, from the University of Heidelberg, Germany, presented findings at the Phase III AGO-OVAR 2.29 trial (NCT03353831), regarding the efficacy and safety of atezolizumab in combination with bevacizumab and chemotherapy for recurrent ovarian cancer in patients not suitable for platinum therapy. The Phase III randomized, double-blind, phase III study, enrolled 574 patients who received either atezolizumab or placebo alongside weekly paclitaxel or pegylated liposomal doxorubicin (PLD) and bevacizumab until disease progression or intolerable toxicity. Despite prior promising results from other trials, AGO-OVAR 2.29 did not demonstrate a significant improvement in overall survival (OS) or progression-free survival (PFS) with the addition of atezolizumab. Safety profiles were as expected, with adverse events reported in both treatment arms. These findings indicate that the inclusion of atezolizumab in this treatment regimen did not confer a substantial clinical benefit in this patient population. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.